Cargando…

Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis

BACKGROUND: Recently, several newer antiplatelet treatment strategies have been used in patients with coronary artery disease (CAD). Apart from the dual antiplatelet therapy (DAPT) consisting of aspirin and clopidogrel, double dose clopidogrel (DDC), triple antiplatelet therapy (TAPT) consisting of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuo, Xiaojun, Zhuo, Bi, Ouyang, Shenyu, Niu, Pei, Xiao, Mou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122215/ https://www.ncbi.nlm.nih.gov/pubmed/30176938 http://dx.doi.org/10.1186/s40360-018-0247-9

Ejemplares similares

In-hospital, short-term and long-term adverse clinical outcomes observed in patients with type 2 diabetes mellitus vs non-diabetes mellitus following percutaneous coronary intervention: A meta-analysis including 139,774 patients
por: Zhuo, Xiaojun, et al.
Publicado: (2019)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
por: Choi, Woong Gil, et al.
Publicado: (2021)

Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease
por: Orme, Rachel C., et al.
Publicado: (2018)

Impact of Grapefruit Juice on the Antiplatelet Activity of Loading and Maintenance Doses of Clopidogrel in Healthy Volunteers
por: Campbell, Jennifer A., et al.
Publicado: (2014)

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
por: Neubauer, Horst, et al.
Publicado: (2011)

Calcium channel blockers reduce the antiplatelet effect of clopidogrel
por: Siller-Matula, Jolanta M, et al.
Publicado: (2008)

Mapping the antiplatelet effects of clopidogrel and aspirin by modified thromboelastography
por: Hemlata,, et al.
Publicado: (2013)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
por: Qu, Jianyu, et al.
Publicado: (2021)

Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers
por: Seo, Kwon-Duk, et al.
Publicado: (2014)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
por: Amin, Arwa M., et al.
Publicado: (2017)

Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention
por: Jeong, Young-Hoon, et al.
Publicado: (2012)

Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis
por: Jin, Jing, et al.
Publicado: (2021)

Celecoxib Does Not Attenuate the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Volunteers
por: Lee, Wonjae, et al.
Publicado: (2010)

Double‐Dose Versus Standard‐Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
por: Bossard, Matthias, et al.
Publicado: (2017)

Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome
por: Kang, Min Gyu, et al.
Publicado: (2022)

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial
por: Li, Yi, et al.
Publicado: (2020)

Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention
por: Adamiak-Giera, Urszula, et al.
Publicado: (2020)

Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease
por: Tresukosol, Damrus, et al.
Publicado: (2014)

Postoperative Bleeding Risk for Oral Surgery under Continued Clopidogrel Antiplatelet Therapy
por: Gröbe, Alexander, et al.
Publicado: (2015)

Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel
por: Cirillo, Plinio, et al.
Publicado: (2020)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
por: Kiebist, Jan, et al.
Publicado: (2021)

Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment
por: Kang, Hyun Goo, et al.
Publicado: (2021)

Analysis of Gastrointestinal Prophylaxis in Patients Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel
por: Morneau, Kathleen M., et al.
Publicado: (2014)

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
por: Obayashi, Yuki, et al.
Publicado: (2022)

Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation
por: Marcano, Ana Lucrecia, et al.
Publicado: (2022)

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease
por: Zhang, Yan-Jiao, et al.
Publicado: (2022)

Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention
por: Gao, Song-Tao, et al.
Publicado: (2023)

Can doubling the maintenance dose of clopidogrel prevent from early stent thrombosis after the primary percutaneous coronary intervention?
por: Roghani, Farshad, et al.
Publicado: (2011)

Prolonged double antiplatelet therapy vs association of antiplatelet and low dose of anticoagulant therapy: PEGASUS or COMPASS?
por: Brunetti, Natale Daniele, et al.
Publicado: (2019)

Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance
por: Chen, Jingyu, et al.
Publicado: (2016)

Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea
por: Choi, Yoon Jin, et al.
Publicado: (2017)

Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
por: Hoshino, Haruhiko, et al.
Publicado: (2021)

Prophylactic Add-on Antiplatelet Therapy in Chronic Kidney Disease With Type 2 Diabetes Mellitus: Comparison Between Clopidogrel and Low-dose Aspirin
por: Dash, Amitabh, et al.
Publicado: (2013)

Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel
por: Zhong, W‐P, et al.
Publicado: (2017)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial
por: Marcantoni, Emanuela, et al.
Publicado: (2022)

Aspirin vs Clopidogrel: Antiplatelet Agent of Choice for Those With Recent Bleeding or at Risk for Gastrointestinal Bleed
por: Gosavi, Siddharth, et al.
Publicado: (2023)

Effects of switching from clopidogrel to prasugrel at the chronic phase after coronary stenting on antiplatelet action and vascular endothelial function: Switch-Pras study
por: Masuyama, Taiki, et al.
Publicado: (2020)

Dual Antiplatelet Therapy in Coronary Artery Disease
por: Sharma, Raghav, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i1jhn6ku5iob7016t6sb9gr1bt